Stanford AI Study Identifies BRP, a Peptide That Reduced Food Intake in Animals

BRP offers a possible new direction for obesity research: a short peptide that appears to influence appetite and metabolism through pathways distinct from those targeted by semaglutide. Stanford researchers found it using an AI-assisted screening method, then observed reduced food intake in lean mice and miniature pigs. Those results make BRP a candidate for further study, but they don't show that it can safely reduce body weight in people. The gap between an effect in animals and a useful treatment is still the central question.

AI narrowed thousands of candidates to one peptide

The team’s March 2025 study began with peptide hormones involved in energy regulation, a broad set of molecules that can carry signals affecting how the body manages food and metabolism. The researchers’ algorithm screened 20,000 protein-coding genes and identified 373 prohormones containing 2,683 peptides. They then narrowed the list to sequences considered likely to be active in the brain and tested 100 candidates. One peptide, a 12-amino-acid molecule named BRP, stood out in that process.

The scale of the search helps explain why computational screening mattered. Peptide hormones can be difficult to pick out among more common byproducts created as proteins are broken down and processed. An algorithm can help rank possible candidates for laboratory testing, but ranking isn't the same as confirming a biological effect. That still requires experiments. The study was published in Nature in March 2025.

That distinction is easy to lose when a discovery is described as AI-driven. Here, the method helped researchers reduce a large search space and choose candidates to test; the evidence about BRP came from the subsequent experiments. The result is a research lead, not a machine-generated answer to obesity.

BRP appears to act through a narrower pathway

Semaglutide targets receptors found in the brain, gut, pancreas and other tissues. Katrin Svensson, the study’s lead author and a Stanford assistant professor of pathology, said BRP appears to act specifically in the hypothalamus, a brain region involved in appetite and metabolism. That reported difference gives researchers a reason to ask whether BRP’s effects might be distinct from those of GLP-1 drugs. It doesn't yet show that a narrower apparent site of action will mean fewer side effects, better results, or a more convenient treatment.

In experiments involving lean mice and miniature pigs, researchers gave BRP by intramuscular injection before feeding. Food intake fell by as much as 50% over the following hour. The pig model was included because its eating and digestion more closely resemble human patterns than a mouse’s, but that resemblance doesn't make the results equivalent to a human trial. The researchers also observed metabolic and neuronal activity distinct from activity associated with GLP-1 or semaglutide. The finding is intriguing; the animal evidence doesn't establish that BRP will produce similar effects in people.

The reported time window matters. A reduction in food intake over an hour is a specific experimental observation, not evidence of sustained weight loss or long-term appetite control. The available findings also concern lean animals, so they don't establish how BRP might behave in animals with obesity. Those are unanswered research questions, not details that can be filled in from the current results.

This is more significant than it looks as a basic research finding: the study points to a possible appetite-related pathway that differs from the one associated with semaglutide. But a different pathway is a starting point for comparison, not proof of an advantage. (And this is the part most people overlook.) An early signal can justify further work while leaving the practical value of a treatment entirely unsettled.

Human testing remains ahead

Svensson has co-founded a company to pursue clinical trials. Before BRP could be assessed in people, researchers are working on ways to extend its effects and make dosing more convenient. Those efforts point to practical issues that often shape whether a biological discovery can become a treatment: how long an effect lasts and how a candidate might be administered. The available information doesn't say what solutions the researchers will use or how long that work will take.

Human safety and effectiveness results haven't been reported, and no trial timeline was confirmed in the available information. That leaves basic questions unanswered, including whether the animal findings translate to people and whether any effect can be maintained under human testing. If you're working in this space, the next useful evidence won't be another comparison based only on mechanism; it'll be results showing how BRP performs in people.

For now, BRP is an early research candidate, not an established alternative to semaglutide. The study offers a plausible reason to investigate it further, while its limits remain plain: the reported appetite effects come from animal experiments, and work on duration and dosing is ongoing. Human testing is the next meaningful milestone. Until results from that stage exist, BRP's potential remains just that. A lead to follow.